Putting adoptive T cell therapy on the path to regulatory approval

Using Hsp90 inhibitors in the clinic: what have we learned?

Radiogenomic evaluation of tumour response to targeted agents

Mutant-specific kinase inhibitors and TAT highlights

New drugs and targets in haematological malignancies

Drugging the cancer genome to overcome drug resistance

ecancermedicalscience editor's choice for February 2015

Effectiveness of adjuvant chemotherapy on patients with bladder cancer

ASCO GU 2015 news roundup

Taxane response in prostate cancer may not be influenced by androgen receptor variations

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma